Abstract: Topical compositions comprising cannabinoids in combination with one or more humectants and one or more penetration enhancers are provided. Also provided are methods comprising applying a topical cannabinoid composition provided herein to the skin areas of a subject affected by inflammation and/or pain associated with musculoskeletal disease or condition and uses of a topical cannabinoid formulation provided herein for the treatment of inflammation and/or pain associated with musculoskeletal disease or condition in a subject.

Abstract: The present invention relates to a food composition for relieving stress, and specifically, to a food composition for relieving stress, which reduces secretion of the stress hormone cortisol and increases secretion of the happy hormone serotonin by containing fermented and aged noni and calamansi as active ingredients, has no side effects, and is safe for the human body. The composition of the present invention may be used as a health functional food or a pharmaceutical composition. The composition of the present invention has an excellent anti-stress effect.

Abstract: The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.

Abstract: In the invention, a pharmaceutical composition is provided, comprising a first and a second peptide. The first peptide is a peptide of the bacteriocin PLNC8 ??, wherein the peptide of the bacteriocin PLNC8 ?? is a peptide A having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) with SEQ ID NO 1, or a peptide B having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) with SEQ ID NO 2. When the first peptide is peptide A, the second peptide B? having 14 to 34 amino acids and comprising a peptide having at least 90%>, 95%>, 96%>, 97%>, 98%> or 99% sequence identity (% SI) with SEQ ID NO 3. When the first peptide is peptide B, the second peptide A? having 15 to 29 amino acids and comprising a peptide having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) with SEQ ID NO 4. The pharmaceutical composition further comprises at least one antibiotic. The pharmaceutical composition may be used in the treatment or prophylaxis of a bacterial infection.

Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.

Abstract: The present invention is directed to methods of treating hypertriglyceridemia or hypertriglyceridemia-related diseases in a subject by using recombinant PRAP1 polypeptides. According to some embodiments of the present disclosure, the subject is a human, in which the recombinant PRAP1 polypeptide comprises the amino acid sequence 100% identical to SEQ ID NO: 1 or 2. According to certain embodiments of the present disclosure, the subject is a mouse, in which the recombinant PRAP1 polypeptide comprises the amino acid sequence 100% identical to SEQ ID NO: 3 or 4.

Abstract: The present disclosure generally relates to systems and methods for delivering humanin and/or other peptides to a subject. In some cases, these may be used for treating or preventing aging skin, or for other diseases. Non-limiting examples of other peptides include mitochondrial-derived peptides such as HNG or MOTS-c. In addition, certain embodiments are generally directed to treatments that can be delivered using topical compositions applied to the skin. For example, in some cases, the composition includes lecithin and/or other components that may facilitate delivery through the skin. Further, certain embodiments may include active ingredients such as tributyrin or 2,6-dimethyl-L-tyrosine, which may interact with humanin or other peptides. Compositions such as these may be used in certain embodiments, for example, to reduce inflammation within the skin, or as an anti-aging treatment, etc.

Abstract: Methods and compositions for treating a disorder of cardiac muscle and/or skeletal muscle in a subject according to aspects of the present disclosure. Treatment methods include administering a therapeutically effective dose of a C-terminal portion of troponin I capable of reducing sensitivity of cardiac muscle and/or skeletal muscle to Ca2+ without decreasing maximum force production. Assays for identification of compounds capable of reducing sensitivity of cardiac muscle and/or skeletal muscle to Ca2+ without decreasing maximum force production are further provided.

Abstract: This application generally relates to stable peptide compositions and kits comprising low levels of buffering and chelating agents, and methods of using the same.

Abstract: The present invention relates to the activation of FGF10 signaling pathway for use in the treatment of a heart disease.

Abstract: The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a ?-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.

Abstract: This invention relates to novel fusion peptides and immunogenic compositions containing the fusion peptides useful in the control and prevention of tick infestations. The invention also relates to compositions comprising said fusion peptides, methods of vaccination against tick infestation using said fusion peptides and compositions, and kits for use with such compositions and methods.

Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens are disclosed. Methods of treating a subject with a Survivin-expressing tumor and methods of preventing a Survivin-expressing tumor are disclosed. Synthetic consensus Survivin antigens are disclosed.

Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Abstract: Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.

Abstract: Provided herein are methods of use of subunit immunogenic compositions, in particular for the prevention and treatment of Zika virus infections.

Abstract: The invention relates to a nucleic acid encoding a polypeptide comprising a plurality of conserved peptide sequences, or variants thereof, wherein the conserved sequences are conserved across one or more HPV genotypes 16, 18, 31, 52, 53, and 58; and wherein the polypeptide comprises a conserved peptide sequence of each of the HPV proteins E1, E2, E4, E5, E6, and E7; and associated vaccines, viral vectors, treatment and prophylaxis.

Abstract: This document describes a number of different polypeptide sequences, and the nucleic acid sequences encoding such polypeptide sequences, that can be used alone or in combination as universal vaccines against viruses including influenza A or influenza B in humans or influenza in swine.

Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.

Abstract: The invention relates to compounds of formula (I) and their use in eliciting a pro-Thl7 immune response. Further provided are methods of production of said compounds. (Formula I) wherein m is an integer between 4 and 13; n is an integer between 4 and 13; x is an integer between 4 and 13; y is an integer between 4 and 13.

Abstract: Compositions and methods incorporating Adenosine deaminase-1 (ADA-1) as an adjuvant. Polynucleotides encoding novel coding sequences, polypeptides, vectors containing same, and methods of use are provided. ADA-1 is identified herein as a molecule that is able to enhance differentiation of TFH cells and thus is useful as a adjuvant in vaccine development.

Abstract: The field of various phototriggered drug release and photoreactions, including reactions generally based on triplet-triplet energy transfer with light excitation at long wavelengths. Systems and methods for absorbing energy in a photosensitizer, and methods for making or using such systems, kits including such systems. The systems and methods comprise transferring that energy by triplet-triplet energy transfer to cleave a cleavable or other active moiety, for instance, in order to cause the release of a releasable moiety. In some cases, these may be contained within a suitable carrier material, for example, a particle or a micelle. Such systems and methods may be used in a variety of applications, including various biological or physical applications. For example, such systems and methods may be useful for delivering drugs or other releasable moieties to regions of a subject.

Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.

Abstract: The present invention relates to oligomers, polymers and lipidoids comprising characteristic oligo(alkylene amine) moieties which are useful as vehicles for transfecting a cell with RNA. The present invention furthermore relates to a composition comprising at least a nucleic acid and an oligomer or polymer or a lipidoid comprising such oligo(alkylene amine) moieties and to a method of transfecting a cell using said composition. Furthermore, the present invention relates to pharmaceutical compositions and uses.

Abstract: Provided herein are polypeptides comprising one or more non-native cysteine residues that form a disulfide bridge between non-native cysteines within the protein or between non-native cysteines of two monomers of the protein. Such modified human polypeptides are useful in treatment of genetic diseases via enzyme replacement therapy and/or gene therapy.

Abstract: Provided herein are adeno-associated virus (AAV) compositions that can express a phenylalanine hydroxylase (PAH) polypeptide in a cell, thereby restoring the PAH gene function. Also provided are methods of use of the AAV compositions, and packaging systems for making the AAV compositions.

Abstract: The present invention relates to a complex of formula (II) constituted of at least 90% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae: The present invention also relates to a process for preparing and purifying said complex of formula (II), and also to a composition comprising said complex.

Abstract: The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds.

Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.

Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.

Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.

Abstract: The present invention refers to cells from a subpopulation of progenitors of endothelial cells loaded with gold nanoparticles sensitive to excitation with infrared radiation with consequent release of thermal energy, to a composition having a plurality of these cells and to their use in the diagnosis and treatment of solid tumours thanks to the selective localization of the composition in the tumour mass, which can be thus identified easily for diagnostic purposes by marking the cells with appropriate marking agents, or treated by stimulation with pulsed laser beam up to the complete cauterization of the tumour mass for a targeted and highly effective therapeutic action.

Abstract: To provide a dental photocurable composition having good storage stability of a matrix containing a polymerizable monomer and a polymerization initiator, etc. and excellent mechanical strength of a dental photocurable composition comprising a mixture of the matrix and a filler. The dental photocurable composition of the present disclosure comprises a matrix containing (A) polymerizable monomer, (B) photosensitizer, (C) photoacid generator and (D) photopolymerization accelerator, and (E) filler, wherein, the dental photocurable composition comprises (A1) polymerizable monomer having an acidic group as the (A) polymerizable monomer, and the dental photocurable composition comprises (D1) tertiary aliphatic amine compound having Log P of 2 or more and pKa of 10 or less as the (D) photopolymerization accelerator.

Abstract: Disclosed are skincare formulations, delivery systems and treatment methods containing an oligopeptide and a combination of antioxidants for topical application to the skin before and/or after dermatological procedures that affect the skin's barrier. The systems herein alleviate discomfort and enable rapid healing of irritated and damaged skin, and provide improved treatment outcomes for dermatological procedures. The disclosed topical formulations, delivery systems, and methods thereof provide enhanced penetration of the active ingredients to the skin while maintaining skin moisture and protecting sensitive skin after dermatological procedures for improvement of aesthetic skin properties. Also provided are methods for therapeutic treatment of dermatological conditions by topically applying, using, for example, a pre-moistened bio-cellulose mask, a formulation comprising (% w/w) at least 0.0001% palmitoyl sh-tripeptide-4 amide on an active basis and at least 0.1% Camellia sinensis leaf extract.

Abstract: An oral hygiene composition includes a mixture of: (i) a carrier liquid; and (ii) a water-insoluble hydratable polymer fibers forming an entangled three-dimensional network of said water-insoluble hydratable polymer fibers in said carrier; wherein: said carrier liquid comprises one or more humectant in a concentration of total humectant in excess of 5 wt. % based on the weight of the composition; said composition has an elastic modulus G? and a loss modulus G?, and said elastic modulus G? is larger that said loss modulus G?; and said water-insoluble hydratable polymer fibers have a diameter of about 10 to about 20,000 nm and a length of at least 100 nm.

Abstract: Described herein, a water-soluble personal cleansing product, its uses, methods and kit, preferably a water-soluble facial cleansing product, comprising a water-soluble fibrous structure; wherein the water-soluble fibrous structure comprises a plurality of fibrous elements; wherein the plurality of fibrous elements comprises: one or more fibrous element-forming materials comprising one or more hydroxyl polymers comprising a natural starch and/or a modified starch; wherein the plurality of fibrous elements is substantially free of surfactant; wherein the water-soluble personal cleansing product comprises one or more surfaces wherein the one or more surfaces are coated with an oily composition, wherein the oily composition comprises one or more oil ingredients. Alternatively, the one or more surfaces are coated with a cleansing composition comprising one or more surfactants; and wherein the cleansing composition is substantially free of alkyl sulfate and alkyl ether sulfate type of surfactants.

Abstract: An aerosol cosmetic composition is provided that includes an oil soluble gloss enhancing film forming component, a solvent, a colorant, a propellant, and useful for application to hair or skin. An aerosol dispensing system and a method of preparing an aerosol sprayable color composition are also provided.

Abstract: Provided is a semi-permanent hair dye composition, and particularly, a foam-type semi-permanent hair dye composition which is easily applied onto the inner part of the hair due to having high foam forming ability and high foam retention and exhibits less color fading after dyeing and excellent colorability. The semi-permanent hair dye composition includes a pigment penetration agent, a cationic surfactant, and a non-ionic surfactant as well as a basic pigment.

Abstract: A liquid fragrance composition contains (i) 3 wt % to 40 wt % of a fragrance, (ii) 0.5 wt % to 5 wt % of glyceryl ricinoleate, and (iii) 60 wt % to 95 wt % of water. Also disclosed are consumer products containing such a liquid fragrance composition.

Abstract: The present disclosure relates to a composition for lightening keratin fibres, comprising (a) hydrogen peroxide; (b) one or more carbonates and/or one or more carbonate-generating systems in a content of greater than or equal to 0.2%, relative to the weight of the composition, (c) one or more polyphosphorus derivatives, in a total content of greater than or equal to 0.5% by weight, relative to the total weight of the composition, and (d) one or more peroxygenated salts, said polyphosphorus derivative(s) being different from said peroxygenated salt(s). The pH of the composition is less than or equal to 10. The present disclosure also relates to a process of using the composition for lightening keratin fibres, and a device comprising the composition.

Abstract: The application relates to personal care products (e.g., deodorants and/or antiperspirants) that can provide a sweat reduction effect without the use of aluminum salts. In one aspect, the compositions comprise a metal oxalate (i.e., potassium oxalate or potassium titanium oxalate). Methods of preparing the personal care composition and uses of the personal care composition are also disclosed.

Abstract: The present disclosure relates to a peptide consisting of an amino acid sequence of SEQ ID NO: 1, 2, 3, or 4, a pharmaceutical composition for preventing or treating skin disease including the peptide, a cosmetic composition for skin condition improvement including the peptide, a food composition for skin condition improvement including the peptide, a method of preventing or treating skin disease using the peptide, and a use of the peptide in preventing or treating skin disease or improving skin condition.

Abstract: Topical formulations of L-ascorbic acid dissolved in a combination of a sugar alcohol agent, and a non-aqueous skin-compatible solvent are provided. The formulations are storage stable for an extended period of time without significant degradation of the L-ascorbic acid in the composition, and have desirable physical properties. The topical formulations can include high concentrations of the L-ascorbic acid. Topical compositions of this disclosure find use in treating or preventing a variety of cosmetic and/or dermatological conditions as well as to reduce the appearance of chronological and/or environmentally-caused skin aging.

Abstract: The present disclosure relates to stable cosmetic compositions containing high amounts of acetyl trifluoromethylphenyl valylglycine. The cosmetic compositions further include high amounts of hydroxypropyl tetrahydropyrantriol, taurate copolymers, fatty alcohols, fatty compounds (other than the fatty alcohols), nonionic emulsifiers, and water. Methods for stabilizing cosmetic compositions containing high amounts of acetyl trifluoromethylphenyl valylglycine and methods for treating the skin with the cosmetic compositions is also described.

Abstract: A cosmetic composition including: (A) a silicone film-forming agent, (B) a high-molecular-weight organopolysiloxane having a degree of polymerization of 2,350 or more and 20,000 or less, and (C) an organopolysiloxane having a cationic group other than the component (A) and the component (B). A total content of the components (A) to (C) in the cosmetic composition is 2% by mass or more and 50% by mass or less, and a content of water is 10% by mass or less.

Abstract: The present invention relates to the use of a milk whey protein hydrolysate for preventing or treating transepidermal water loss (TEWL) and/or TEWL-associated disorders or/and enhancing skin barrier function in young and adult mammals. The protein hydrolysate may be used in the prevention or treatment of TEWL-associated disorders, such as atopic dermatitis, dry or reactive skin or skin dehydration. It may also be used in the cosmetic use of improving skin appearance.

Abstract: A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.

Abstract: The invention relates to a nasally administrable composition comprising at least one active substance in magnesium-containing vesicular carrier, said carrier comprising glycol, phospholipids, water and at least one magnesium source. Methods for nasal administration of the composition, for example, for pain relief, are also provided.

Abstract: Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat inflammatory bowel disease, or to prevent a relapse. The enema for rectal application containing budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 6 weeks in order to treat inflammatory bowel disease, or to prevent a relapse; the enema for rectal application described above, in which a dose of budesonide is 2.0 mg per dose; the enema for rectal application according to any one of the above, which is taken in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse; the enema for rectal application according to any one of the above, which has a foamy shape or a liquid shape.

Abstract: A medical foam for delivering an active agent to a patient includes a biocompatible composition configured to form a foam, an active agent dissolved, dispersed, or suspended in the biocompatible composition, and a gas including nitrous oxide. The biocompatible composition may be configured to form a gel at a temperature of about 37° C. A method for administering an active agent to a patient includes preparing a mixture comprising a foamable liquid and the active agent, incorporating a gas comprising nitrous oxide into the mixture to create a foam containing the active agent, introducing the foam into a body cavity of the patient, and contacting the foam with a tissue surface in the body cavity.